期刊文献+

Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy 被引量:3

Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy
下载PDF
导出
摘要 AIM To report early imaging assessment of ablated area post electrochemotherapy(ECT) in patients with locally advanced pancreatic cancer(LAPC). METHODS ECT was performed in 19 LAPC patients enrolled in an approved ongoing clinical phase Ⅰ/Ⅱ study. Before and after ECT, 18 patients underwent computed tomography(CT) scan, 11 patients underwent morphological and functional magnetic resonance(MR) scan(dynamic contrast enhanced-MRI) calculating wash-in slope(WIS) and wash-out slope(WOS); diffusion weighted imaging calculating pseudo-diffusivity(Dp), perfusion fraction(fp) and tissue diffusivity(Dt); 10 patients underwentpositron emission tomography(PET). Response evaluation criteria in solid tumour(RECIST) on MR and CT were used to assess tumour therapy response. Choi on CT, PET response criteria in solid tumors(PERCIST) on PET and functional parameters on MR were used to evaluate treatment response.RESULTS For each patient no significant reduction was measurable by CT and MR using RECIST. According Choi criteria a partial response was obtained in 18/18(100.0%) patients. According PERCIST criteria 6/10(60.0%) patients showed a partial response, 3/10(30.0%) stable disease and 1/10(10.0%) progression disease. Moreover, using functional MR parameters, a significant reduction of viable tumour after ECT can be observed. According ΔWIS and ΔWOS 9/11(81.8%) patients exhibited a partial response and 2/11(18.2%) stable disease; 8/11(72.7%) patients were considered in partial response by ΔDp evaluation and 3/11(27.3%) in stable disease; according ΔDt 7/11(63.6%) patients showed a partial response, 1/11(9.1%) showed progression of disease and 3/11(27.3%) were stable. Perfusion fraction fp showed a significant reduction after ECT only in four patients. No significant difference was observed after ECT in signal intensity of T1-weighted images and T2-weighted images, and in equilibrium-phase of contrast study, according to χ2 test was observed. A good correlation was reported between ΔHounsfield unit and Δmaximum standardized uptake value and between Δfp and ΔWOS, with a significant statistically difference(P < 0.05) using Spearman correlation coefficient.CONCLUSION Perfusion and diffusion MR derived parameters, Choi, PERCIST criteria are more performant than morphological MR and CT criteria to assess ECT treatment response. To report early imaging assessment of ablated area post electrochemotherapy (ECT) in patients with locally advanced pancreatic cancer (LAPC). METHODSECT was performed in 19 LAPC patients enrolled in an approved ongoing clinical phase I/II study. Before and after ECT, 18 patients underwent computed tomography (CT) scan, 11 patients underwent morphological and functional magnetic resonance (MR) scan (dynamic contrast enhanced-MRI) calculating wash-in slope (WIS) and wash-out slope (WOS); diffusion weighted imaging calculating pseudo-diffusivity (Dp), perfusion fraction (fp) and tissue diffusivity (Dt); 10 patients underwent positron emission tomography (PET). Response evaluation criteria in solid tumour (RECIST) on MR and CT were used to assess tumour therapy response. Choi on CT, PET response criteria in solid tumors (PERCIST) on PET and functional parameters on MR were used to evaluate treatment response. RESULTSFor each patient no significant reduction was measurable by CT and MR using RECIST. According Choi criteria a partial response was obtained in 18/18 (100.0%) patients. According PERCIST criteria 6/10 (60.0%) patients showed a partial response, 3/10 (30.0%) stable disease and 1/10 (10.0%) progression disease. Moreover, using functional MR parameters, a significant reduction of viable tumour after ECT can be observed. According ΔWIS and ΔWOS 9/11 (81.8%) patients exhibited a partial response and 2/11 (18.2%) stable disease; 8/11 (72.7%) patients were considered in partial response by ΔDp evaluation and 3/11 (27.3%) in stable disease; according ΔDt 7/11 (63.6%) patients showed a partial response, 1/11 (9.1%) showed progression of disease and 3/11 (27.3%) were stable. Perfusion fraction fp showed a significant reduction after ECT only in four patients. No significant difference was observed after ECT in signal intensity of T1-weighted images and T2-weighted images, and in equilibrium-phase of contrast study, according to χ<sup>2</sup> test was observed. A good correlation was reported between ΔHounsfield unit and Δmaximum standardized uptake value and between Δfp and ΔWOS, with a significant statistically difference (P < 0.05) using Spearman correlation coefficient. CONCLUSIONPerfusion and diffusion MR derived parameters, Choi, PERCIST criteria are more performant than morphological MR and CT criteria to assess ECT treatment response.
出处 《World Journal of Gastroenterology》 SCIE CAS 2017年第26期4767-4778,共12页 世界胃肠病学杂志(英文版)
关键词 可逆 electroporation 反应评价 正电子排放 tomography/computed 断层摄影术 胰腺的癌症 磁性的回声成像 Reversible electroporation Response assessment Positron emission tomography/computed tomography Pancreatic cancer Magnetic resonance imaging
  • 相关文献

参考文献3

二级参考文献12

  • 1Min-Hua Chen Wei Yang Kun Yan Wen Gao Ying Dai Yan-Bin Wang Xiao-Peng Zhang Shan-Shan Yin.Treatment efficacy of radiof requency ablation of 338 patients with hepatic malignant tumor and the relevant complications[J].World Journal of Gastroenterology,2005,11(40):6395-6401. 被引量:25
  • 2MitsuoToyoda,KatsuhikoHoriuchi,KenjiKatakai,SatoruKakizaki,NaondoSohara,KenSato,HitoshiTakagi,MasatomoMori,Takahito Nakajima.Computed tomography-guided transpulmonary radiofrequency ablation for hepatocellular carcinoma located in hepatic dome[J].World Journal of Gastroenterology,2006,12(4):608-611. 被引量:18
  • 3Brian A. Boone,Jennifer Steve,Alyssa M. Krasinskas,Amer H. Zureikat,Barry C. Lembersky,Michael K. Gibson,Ronald G. Stoller,Herbert J. Zeh,Nathan Bahary.Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer[J].J Surg Oncol.2013(4)
  • 4Matthew H. G. Katz,Robert Marsh,Joseph M. Herman,Qian Shi,Eric Collison,Alan P. Venook,Hedy L. Kindler,Steven R. Alberts,Philip Philip,Andrew M. Lowy,Peter W. T. Pisters,Mitchell C. Posner,Jordan D. Berlin,Syed A. Ahmad.Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design[J].Annals of Surgical Oncology.2013(8)
  • 5Caroline S. Verbeke.Resection Margins in Pancreatic Cancer[J].Surgical Clinics of North America.2013(3)
  • 6Pavlos Papavasiliou,Yun Shin Chun,John P. Hoffman.How to Define and Manage Borderline Resectable Pancreatic Cancer[J].Surgical Clinics of North America.2013(3)
  • 7Gregory A. Coté,Jeffrey Smith,Stuart Sherman,Kimberly Kelly.Technologies for Imaging the Normal and Diseased Pancreas[J].Gastroenterology.2013(6)
  • 8Somnath Mukherjee,Christopher N Hurt,John Bridgewater,Stephen Falk,Sebastian Cummins,Harpreet Wasan,Tom Crosby,Catherine Jephcott,Rajarshi Roy,Ganesh Radhakrishna,Alec McDonald,Ruby Ray,George Joseph,John Staffurth,Ross A Abrams,Gareth Griffiths,Tim Maughan.Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial[J].Lancet Oncology.2013(4)
  • 9F. Calvo,C. Guillen Ponce,M. Mu?oz Beltran,A. Sanjuanbenito Dehesa.Multidisciplinary management of locally advanced–borderline resectable adenocarcinoma of the head of the pancreas[J].Clinical and Translational Oncology.2013(3)
  • 10Krishna S. Gunturu,Xiaopan Yao,Xiangyu Cong,Jaykumar R. Thumar,Howard S. Hochster,Stacey M. Stein,Jill Lacy.FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity[J].Medical Oncology.2013(1)

共引文献38

同被引文献25

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部